Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors
The purpose of this study is to establish the Maximum Tolerated Dose (MTD) of OXi4503 given by weekly infusions to patients with advanced solid tumors.
Solid Tumors
DRUG: OXi4503
To establish the Maximum Tolerated Dose (MTD) of OXi4503 given by weekly intravenous infusions., 4 weeks
To investigate the pharmacokinetic (PK) and pharmacodynamic (PD) behavior of OXi4503., 4 weeks
The purpose of this study is to establish the Maximum Tolerated Dose (MTD) of OXi4503 given by weekly infusions to patients with advanced solid tumors.